A patient death has prompted Atara Biotherapeutics to issue a voluntary hold on patient recruitment into its potentially groundbreaking phase 1 trial of the CAR-T cell therapy ATA2271 for pleural…

Amgen has become the latest company to discontinue development of an obesity drug candidate from what had been an emerging class of medicines based on growth/differentiation factor-15 (GDF-15) protein. Source:…

The Senate voted 65-27 yesterday evening to pass a continuing resolution that will keep the federal government funded through March 11. Source: Drug Industry Daily

In an unusual move, the FDA has backed off deadlines in a recent draft guidance on Coronavirus Aid, Relief and Economic Security (CARES) Act information reporting after the industry lodged…

Fort Lauderdale, Fla.-based ECI Pharmaceuticals has received a warning letter from the FDA, which said the generic drugmaker incorrectly listed two hormone products on FDA’s Drug Registration and Listing System…

Johnson & Johnson (J&J) has struck a deal with Remix Therapeutics — newly launched in late 2020 — to develop small-molecule therapeutics capable of reprogramming RNA processing for up to…

Merck and Curve Therapeutics have struck a collaboration pact potentially exceeding $1.7 billion to develop drugs for up to five disease targets in oncology and neurology. Source: Drug Industry Daily

Clinical challenges and public health concerns combined to derail an FDA approval for Avenue Therapeutics’ intravenous tramadol for acute pain. Source: Drug Industry Daily

A federal judge has ruled that the government incorrectly threatened AstraZeneca with fines for limiting discounts to the controversial 340B Drug Discount program for safety-net hospitals. Source: Drug Industry Daily

The FDA approved the 100th abbreviated new drug application (ANDAs) through its congressionally established Competitive Generic Therapy (CGT) pathway in 2021, bringing new low-priced medicines to the market for originator…